



ASX/MEDIA RELEASE

17 January 2018

Sirtex Trading Update

Sydney, Australia

Sirtex Medical Limited (ASX:SRX) today announces that its unaudited, first-half Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) for the six months ended 31 December 2017 is expected to be to approximately \$34 million, reflecting 16% growth on the prior corresponding period (pcp).

Worldwide dose sales of SIR-Spheres® Y-90 resin microspheres were flat for the half versus pcp.

Mr Andrew McLean, Chief Executive Officer of Sirtex Medical Limited commented “As a result of recent management initiatives, we anticipate higher sales in the second half, with ongoing targeted reductions in operating expenditure to drive business efficiencies and productivity gains, resulting in forecasted full year EBITDA in the range of \$75-85 million. This compares to an underlying EBITDA¹ of \$61.5 million reported in the 2017 financial year. Cash flow generation is expected to remain strong given our high levels of EBITDA conversion to cash flow coupled with lower investing cash flow, resulting from the completion of our major clinical studies.”

The Company expects to release its full first-half financial results on 21 February 2018.

– ENDS –

¹ FY17 underlying EBITDA excludes clinical and R&D asset impairments, restructuring costs and impairment/write-off of receivables.

About SIR-Spheres® Y-90 Resin Microspheres

SIR-Spheres Y-90 resin microspheres are a medical device used in interventional oncology and delivered via Selective Internal Radiation Therapy (SIRT), also known as radioembolisation, directly to liver tumours. SIR-Spheres Y-90 resin microspheres are approved for supply in key markets, such as the United States, European Union and Australia.

About Sirtex Medical, www.sirtex.com

Sirtex Medical Limited (ASX:SRX) is an Australian based medical device company with global market coverage. Its core revenue producing technology, which has regulatory approvals, is a selective internal radiation therapy (SIRT), with clinically proven applications for liver cancer with approximately 80,000 doses supplied and administered over 1,090 medical centres in more than 40 countries.

Investor Enquiries:

Mr Andrew McLean
CEO
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Head of Investor Relations
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

To subscribe to our email alert service for ASX Announcements, please visit:

<http://www.sirtex.com/au/investors/email-alerts/>

Follow us on Twitter: **@sirtexmedical**

Visit us on LinkedIn: **Sirtex Medical Limited**

SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd